SBIR/STTR Recipient

suitX

Brief Description

suitX brought advanced accessible exoskeletons to industrial and medical markets with funding from venture capital, industry, and government.

Formerly known as U.S. Bionics.

Acquired by Ottobock in 2021.

Timeline 2011. Company founded. 2021. Acquired by Ottobock. Inventors

Homayoon Kazerooni, Adam Zoss, Andre Nguyen Van Qui, Bradley Perry, Christina Yee, Daniel Merala, David Cuban, Dong-Jin Hyun, Dylan Fairbanks, Erich Hacker, Han Woong Bae, James Alden Hatch, Jason Reid, JiaLong James Ren, Jing Song Huang, JJ Kuwata...

Solidus Biosciences, Inc.

Brief Description

Solidus' mission for the pharmaceutical industry is to improve the process of new drug development by providing proprietary decision-enabling technology to enhance drug safety, efficiency, cost, and, thereby, productivity from investment in new drug research and development.

Formerly known as Solidus Networks. Inc.

Timeline 2005. Company founded. Inventors

Douglas Clark, Jonathan Dordick

SMART Pad LLC

Brief Description

SMART Pad is commercializing a completely redesigned Chemical Mechanical Planarization (CMP) pad for the semiconductor industry. CMP processes have not changed much since their introduction by IBM in 1983, consisting of polyurethane polishing pads, polishing slurries with abrasive particles and pad conditioners for pad resurfacing.

SMART Pad co-founder Sunghoon Lee developed the company's foundational technology while earning his PhD in the lab of UC Berkeley Professor of Mechanical Engineering David Dornfeld.

Timeline 2018...

Caribou Biosciences Inc.

Brief Description

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T cell platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases.

...

Scribe Therapeutics

Brief Description

Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders. The molecular engineering company was spun out of discoveries in the lab of UC Berkeley Professor of Biochemistry, Biophysics and Structural Biology and Nobel Laureate Jennifer Doudna. Doudna co-founded Scribe with company CEO Benjamin Oakes, who received a PhD in Molecular and Cellular Biology from UC Berkeley in 2017, where he worked in the Doudna Lab and Savage Lab, UC Berkeley Associate Professor of...

Cortera Neurotechnologies

Brief Description

Cortera Neurotechnologies, Inc. designs medical devices aimed at revolutionizing the treatment of incurable neurological conditions. The company's mission was to deliver innovative products that improve patient care, quality of life and advance neuroscientific research.

Rikky Muller (PhD ’13 EECS) invented the company's foundational technology, a micro-electrocorticography (ECoG) device, as a PhD student in electrical engineering and computer sciences at UC Berkeley. The small implant — as thin as plastic wrap and as flexible as a soft contact lens — can record...

Iaterion

Brief Description

Iaterion is a biopharma company developing novel therapeutics for women's health and diseases. The company develops targeted selective nuclear receptor drugs addressing multiple indications encountered by women and focuses on novel drugs as an alternative to menopausal hormone therapy (MHT). The company was founded to commercialize a novel discovery made by UC Berkeley Adjunct Professor in the Department of Nutritional Sciences Dale Leitman, MD, PhD, for nuclear receptors reprogramming (NRRP) agents.

Iaterion's team brings decades of experience in the bio-...

GenEdit, Inc.

Brief Description

GenEdit develops innovative therapies through targeted delivery of genetic medicines. The GenEdit founders share the vision that recent scientific advancements in engineering CRISPR components and delivery vehicles offer a groundbreaking opportunity to develop safe and effective medicines for genetic diseases.

The company's proprietary Polymer nanoparticle can deliver CRISPR protein and gRNA. CRISPR in a protein form has many advantages, delivery has been a challenge limiting its application. To deliver CRISPR protein, encapsulation of CRISPR ribonucleoprotein (RNP...

Enable Biosciences, Inc.

Brief Description

Enable Biosciences is an early-stage biotech company creating the next generation of tools for predictive medicine, with diagnostics 10,000x more sensitive than previous methods, for earlier detection and treatment of diseases like HIV and type 1 diabetes.

The company was co-founded by UC Berkeley Professor of Chemistry Carolyn Bertozzi, with Drs. Peter Robinson and Jason Tsai, who were PhD students in her lab. In 2022, Dr. Bertozzi shared the Nobel Prize in Chemistry for taking click chemistry, which allows molecules to snap together in a quick and efficient way,...

Q-Chem Inc.

Brief Description

Q-Chem, Inc. is a comprehensive ab initio quantum chemistry program to solve computational problems faster, more accurately and less expensively than ever before possible. Q-Chem's capabilities facilitate applications in pharmaceuticals, materials science, biochemistry, and other fields. Q-Chem also provides users with the highest level of technical support.

Timeline 1993. Company founded 1997. Product in market Inventors

Alex Sodt, Andreas Dreuw, Anna Krylov, Anthony Dutoi, Barry Dunietz, Brian Austin, Chao Ping Hsu; Charles...